iProcess Global Research

Executive Summary

iProcess Global Research is a leading supplier of ethically sourced human biospecimens and integrated laboratory services, supporting pharmaceutical, biotech, and diagnostic R&D worldwide. With a network of over 1,500 collection sites across 30+ countries, the company ensures high-quality samples through ISO 20387-compliant biorepositories and validated cold-chain logistics. It also operates AxisOne, an AI-powered R&D platform that connects researchers to a global network of laboratories for end-to-end scientific services. Founded in 2008 and headquartered in San Diego, iProcess addresses critical bottlenecks in drug discovery by providing reliable, scalable access to diverse biospecimens and advanced lab capabilities. As a private entity, it maintains a strong operational focus without the public market pressures, enabling long-term investments in infrastructure and technology. Its established global footprint and compliance standards position it as a trusted partner in the life sciences ecosystem. The company's growth trajectory is underpinned by increasing demand for outsourced research services and personalized medicine, which require diverse, well-characterized biospecimens. AxisOne's AI-driven platform offers a competitive edge by streamlining vendor selection and project management. Key upcoming catalysts include potential expansion of AxisOne into new therapeutic areas, strategic partnerships with large pharma companies, and geographic expansion into emerging markets like Asia-Pacific. While the company faces competition from other biospecimen providers, its combination of scale, compliance, and digital platform creates differentiation. Long-term success hinges on sustaining sample quality, expanding the platform's capabilities, and navigating regulatory changes across jurisdictions.

Upcoming Catalysts (preview)

• Q2 2026AxisOne platform expansion into new therapeutic areas (e.g., oncology, rare diseases)75% success
• Q3 2026Major partnership agreement with a top-20 pharmaceutical company for exclusive biospecimen supply60% success
• Q4 2026Geographic expansion into Asia-Pacific through new collection sites and local laboratory partnerships70% success